Global Infectious Diseases Partnering 2010-2016: Deal trends, players and financials

Publisher Name :
Date: 01-Nov-2016
No. of pages: 800
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Infectious Diseases Partnering 2010 to 2016 provides the full collection of Infectious Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Infectious Diseases partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Infectious Diseases partnering agreement structure

Infectious Diseases partnering contract documents

Top Infectious Diseases deals by value

Most active Infectious Diseases dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.

The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Infectious Diseases dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Infectious Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Infectious Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Infectious Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Infectious Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2010. The chapter is organized by specific Infectious Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Diseases partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products.

Report scope

Global Infectious Diseases Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Infectious Diseases trends and structure of deals entered into by leading companies worldwide.

Global Infectious Diseases Partnering 2010 to 2016 includes:

Trends in Infectious Diseases dealmaking in the biopharma industry since 2010

Analysis of Infectious Diseases deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Infectious Diseases deal contract documents

Comprehensive access to over 3500 Infectious Diseases deal records

The leading Infectious Diseases deals by value since 2010

Most active Infectious Diseases dealmakers since 2010

The report includes deals for the following indications:

Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications

Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.

Parasitic

Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other fungal indications

Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever, Malaria, West Nile Virus, Yellow fever, plus other tropical indications

In Global Infectious Diseases Partnering 2010 to 2016, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Diseases Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 1,500 infectious diseases deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Infectious Diseases Partnering 2010 to 2016 provides the reader with the following key benefits:

In-depth understanding of Infectious Diseases deal trends since 2010

Access Infectious Diseases deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Infectious Diseases partner companies

Comprehensive access to over 750 links to actual Infectious Diseases deals entered into by the world's biopharma companies

Indepth review of Infectious Diseases deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Infectious Diseases opportunities

Uncover companies actively partnering Infectious Diseases opportunities

Global Infectious Diseases Partnering 2010-2016: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Diseases dealmaking
2.1. Introduction
2.2. Infectious Diseases partnering over the years
2.3. Infectious Diseases partnering by deal type
2.4. Infectious Diseases partnering by industry sector
2.5. Infectious Diseases partnering by stage of development
2.6. Infectious Diseases partnering by technology type
2.7. Infectious Diseases partnering by therapeutic indication

Chapter 3 -Financial deal terms for Infectious Diseases partnering
3.1. Introduction
3.2. Disclosed financials terms for Infectious Diseases partnering
3.3. Infectious Diseases partnering headline values
3.4. Infectious Diseases deal upfront payments
3.5. Infectious Diseases deal milestone payments
3.6. Infectious Diseases royalty rates

Chapter 4 - Leading Infectious Diseases deals and dealmakers
4.1. Introduction
4.2. Most active in Infectious Diseases partnering
4.3. List of most active dealmakers in Infectious Diseases
4.4. Top Infectious Diseases deals by value

Chapter 5 - Infectious Diseases contract document directory
5.1. Introduction
5.2. Infectious Diseases partnering deals where contract document available

Chapter 6 - Infectious Diseases dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Infectious Diseases therapeutic target

Appendices
Appendix 1 - Directory of Infectious Diseases deals by company A-Z 2010 to 2016
Appendix 2 - Directory of Infectious Diseases deals by deal type 2010 to 2016
Appendix 3 - Directory of Infectious Diseases deals by stage of development 2010 to 2016
Appendix 4 - Directory of Infectious Diseases deals by technology type 2010 to 2016
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Infectious Diseases partnering since 2010
Figure 2: Infectious Diseases partnering by deal type since 2010
Figure 3: Infectious Diseases partnering by industry sector since 2010
Figure 4: Infectious Diseases partnering by stage of development since 2010
Figure 5: Infectious Diseases partnering by technology type since 2010
Figure 6: Infectious Diseases partnering by indication since 2010
Figure 7: Infectious Diseases deals with a headline value
Figure 8: Infectious Diseases deals with upfront payment values
Figure 9: Infectious Diseases deals with milestone payment
Figure 10: Infectious Diseases deals with royalty rates
Figure 11: Active Infectious Diseases dealmaking activity- 2010 to 2016
Figure 12: Top Infectious Diseases deals by value since 2010
  • Impetigo - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 45
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H2 2016, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabet......
  • Q Fever - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 41
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Q Fever - Pipeline Review, H2 2016, provides an overview of the Q Fever (Infectious Disease) pipeline landscape.Q fever, also called query fever, is a bacterial infection caused by the bacteria Coxiella burnetii. Common symptoms of Q fever include high fever, cough, headache, diarrhea, nausea, abdominal pain, jaundice and muscle pain. Risk factors include occupations. Treatment includes antibiotics.......
  • Global Niclosamide Market Research Report 2016
    Published: 29-Nov-2016        Price: US 2900 Onwards        Pages: 102
    Notes: Production, means the output of Niclosamide Revenue, means the sales value of Niclosamide This report studies Niclosamide in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Shanxi Hanjiang Pharmaceutical - Anhui Topsun Pharmaceutical - Zhengqing Pharmaceutical Group......
  • Global Meningococcal Infections Vaccine Market Research Report 2016
    Published: 29-Nov-2016        Price: US 2900 Onwards        Pages: 100
    Notes: Production, means the output of Meningococcal Infections Vaccine Revenue, means the sales value of Meningococcal Infections Vaccine This report studies Meningococcal Infections Vaccine in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Sanofi-Pasteur - Beijing Tiantan Biologi......
  • United States Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Market Report 2016
    Published: 29-Nov-2016        Price: US 3800 Onwards        Pages: 100
    Notes: Sales, means the sales volume of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Revenue, means the sales value of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections This report studies sales (consumption) of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Pfizer - Merck - Astra......
  • Global Drugs for Clostridium Difficile Infections Market Research Report 2016
    Published: 28-Nov-2016        Price: US 2900 Onwards        Pages: 102
    Notes: Production, means the output of Drugs for Clostridium Difficile Infections Revenue, means the sales value of Drugs for Clostridium Difficile Infections This report studies Drugs for Clostridium Difficile Infections in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Absynth......
  • United States Ganciclovir Market Report 2016
    Published: 28-Nov-2016        Price: US 3800 Onwards        Pages: 99
    Notes: Sales, means the sales volume of Ganciclovir Revenue, means the sales value of Ganciclovir This report studies sales (consumption) of Ganciclovir in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Roche - Bausch & Lomb - Fresenius Kabi - Luitpold - Huatai Pharmaceutical - Wuhan Hualong Bio-pharmaceutical - Luoxin - HUBEI KEYI ......
  • Europe Voriconazole Market Report 2016
    Published: 25-Nov-2016        Price: US 3900 Onwards        Pages: 119
    Notes: Sales, means the sales volume of Voriconazole Revenue, means the sales value of Voriconazole This report studies sales (consumption) of Voriconazole in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Pfizer - Teva - GeneTech Pharm - Novartis - Mylan - ......
  • Escherichia coli Infections - Pipeline Review, H2 2016
    Published: 23-Nov-2016        Price: US 2000 Onwards        Pages: 165
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H2 2016, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs